Mode
Text Size
Log in / Sign up
N/A N=51 Randomized Double-blind Treatment

Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3

Astigmatism

Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: Tactical Composite Score — 0.34; -0.01; -0.33 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Placebo Lenses (Device); Spherical Lenses (Device); Toric Lenses (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Virginia
Primary completion
Feb 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Tactical Composite Score
0.34; -0.01; -0.33
SECONDARY
Operational Composite Score
-4.06; 2.01; 2.05

Summary

It is a common clinical practice to leave small amounts of astigmatism uncorrected in contact lens wearers. Therefore, some drivers who have astigmatism and wear contact lenses may experience blur while driving. The purpose of this study is to determine if correcting small amounts of astigmatism with contact lenses will improve driving safety.

Eligibility Criteria

Inclusion Criteria

  • Adult licensed driver
  • Ages 18-39 years
  • Corrected vision of 20/40 or better in each eye
  • Astigmatism between 0.75 and 1.75 diopters in each eye
  • Nearsightedness between 0 and -9 diopters in each eye
  • No active eye infection
  • No defective peripheral vision
  • No bifocal correction
  • Routinely wears toric contact lenses (more than 4 times per week)
  • Routinely drives a car (more than 4 times per week)
  • No history of motion, sea, or big screen (e.g. IMAX) sickness, and no persistent Simulation Adaptation Syndrome

Exclusion Criteria

  • Corrected vision worse than 20/40 in either eye
  • No astigmatism in either eye
  • Active eye infection
  • Defective peripheral vision
  • Wears bifocals
  • Wears contact lenses less than 4 times per week
  • Drives infrequently (less than 4 times per week)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02950545). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search